[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488761":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":53,"collaborators":20,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":20,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with vertebral atherosclerotic stenosis requiring stent implantation","EXPERIMENTAL","Referring to \"the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease\", \"the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus\" and \"Subclavian\u002Fextracranial vertebral artery stenosis: Chinese expert consensus\" in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients.",[13],"Device: The drug-eluting stent",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","The drug-eluting stent","Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Zhong Ji, PHD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","020-62787664","jizhong22@hotmail.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":20},"Kaibin Huang","15915751065",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Nanfang Hospital of Southern Medical University","RECRUITING","Guangzhou","Guangdong","510515","China","CN",{"type":43,"coordinates":44},"Point",[45,46],113.25,23.11667,{"lat":46,"lon":45},[49,50],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":51,"role":27,"phone":32,"phoneExt":20,"email":52},"Kaibing Huang","hkb@smu.edu.cn",{"type":24,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"jizhong","Associate chief physician","100488761","efficacy-of-drug-eluting-vertebral-artery-stenting-treatment-for-atherosclerotic-vertebral-arteries-stenosis-100488761",false,"NCT05644314","Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis","Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender is not limited;\n2. Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems;\n3. Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery;\n2. With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery;\n3. Gastrointestinal disease with active bleeding;\n4. Previous myocardial infarction or large-scale cerebral infarction within 2 weeks;\n5. Known contraindications to heparin, rapamycin, anesthesia, and contrast agents;\n6. Life expectancy less than 12 months;\n7. the investigator judged patients to be unsuitable for participation in this study.","ALL","18 Years",{"count":66,"type":67},144,"ESTIMATED","INTERVENTIONAL",[70],"NA","This is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for Atherosclerotic Vertebral Arteries Stenosis. Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.",[73,74],"Ischemic Stroke","Vertebral Artery Stenosis","2023-03-13",{"date":77,"type":78},"2023-03-14","ACTUAL",{"date":80,"type":78},"2022-05-01",{"date":82,"type":67},"2029-05-31",{"name":5,"class":6},1]